Hemocompatibility studies according to ISO 10993-4:2017

You want to identify the risk resulting from the interaction of your medical device with blood?

QUALIblood provides a **comprehensive in vitro package** to run your hemocompatibility studies following ISO 10993-4:2017 guidelines



☑ Coagulation activation on citrated plasma

Clotting time assays (aPTT, PT, TT),
Thrombin-antithrombin complexes (TAT),
Thrombin generation assay (TGA)
Fibrin generation assay (FibIn – FibEx)

☑ Fibrinolytic system activation on citrated plasma

D-Dimers
Fibrin Degradation Products (FDPs)
Fibwave (in house kinetic assay)

☑ Hemolysis on fresh whole blood

Hemoglobin release

☑ Complement system activation on plasma or serum

C3a
C5a
C5b-9

☑ Platelet activation on fresh whole blood and PRP

Platelet count
Flow cytometry: CD62P, Fibrinogen binding, active form of integrin $\alpha_{IIb}\beta_3$
Platelet aggregation
PF4

☑ Hematology – leukocyte activation

Blood cell count
Leukocyte adhesion
Platelet-leukocyte aggregates
NE

Required biological material is provided by QUALIblood

Contact us if you need additional information or a quotation: contact@qualiblood.eu

Your partner in precision bioanalysis
www.qualiblood.eu

QUALIblood